Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04658862




Registration number
NCT04658862
Ethics application status
Date submitted
19/11/2020
Date registered
9/12/2020
Date last updated
22/05/2024

Titles & IDs
Public title
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Scientific title
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy
Secondary ID [1] 0 0
2020-002620-36
Secondary ID [2] 0 0
CR108917
Universal Trial Number (UTN)
Trial acronym
SunRISe-2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Urinary Bladder Neoplasms 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bladder - transitional cell cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Cetrelimab
Treatment: Drugs - TAR-200
Treatment: Drugs - Cisplatin
Treatment: Drugs - Gemcitabine
Treatment: Other - Conventional radiation therapy
Treatment: Other - Hypo-fractioned radiation therapy

Experimental: TAR-200 + Cetrelimab - Participants will receive intravesical TAR-200 every 3 weeks (21 days indwelling) for first 18 weeks and thereafter from Week 24 every 12 weeks through study Year 3 in combination with intravenous (IV) Cetrelimab.

Active Comparator: Chemotherapy (cisplatin or gemcitabine) + Radiation Therapy - Participants will receive chemotherapy based on investigator's choice from either cisplatin intravenously once weekly for 4 to 6 treatment weeks or gemcitabine intravenously twice weekly for 4 to 6 treatment weeks as Standard of Care (SOC) along with radiation therapy from either conventional radiotherapy (64 Gray [Gy], bladder only) for up to 6.5 treatment weeks or hypo-fractionated radiotherapy (55 Gy, bladder only) for up to 4 weeks.


Other interventions: Cetrelimab
Participants will receive intravenous Cetrelimab.

Treatment: Drugs: TAR-200
Participants will receive intravesical TAR-200.

Treatment: Drugs: Cisplatin
Participants will receive cisplatin intravenously.

Treatment: Drugs: Gemcitabine
Participants will receive gemcitabine intravenously.

Treatment: Other: Conventional radiation therapy
Participants will receive conventional radiation therapy for bladder (64 gy).

Treatment: Other: Hypo-fractioned radiation therapy
Participants will receive hypo-fractioned radiation therapy for bladder (55 gy).
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Intervention code [3] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time from Randomization to the First Bladder Intact Event-free Survival (BI-EFS) event
Timepoint [1] 0 0
Up to 8 years
Secondary outcome [1] 0 0
Metastasis-free survival (MFS)
Timepoint [1] 0 0
Up to 8 years
Secondary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Up to 8 years
Secondary outcome [3] 0 0
Overall Response Rate (ORR)
Timepoint [3] 0 0
Up to 8 years
Secondary outcome [4] 0 0
Number of Participants with Adverse Events (AEs) According to Common Terminology Criteria for Adverse Events (CTCAE)
Timepoint [4] 0 0
Up to 8 years
Secondary outcome [5] 0 0
Number of Participants with AEs by Severity according to Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE)
Timepoint [5] 0 0
Up to 8 years
Secondary outcome [6] 0 0
Number of Participants with Clinical Laboratory Abnormalities
Timepoint [6] 0 0
Up to 8 years

Eligibility
Key inclusion criteria
- Ineligible for or have elected not to undergo radical cystectomy

- All adverse events associated with any prior surgery and/or intravesical therapy must
have resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Grade less than (<) 2 prior to randomization

- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2

- Thyroid function tests are within the normal range per investigator assessment (or
stable on hormone supplementation). Investigators may consult an endocrinologist for
participant eligibility assessment in the case of equivocal or marginal test results

- Adequate bone marrow, liver, and renal function: Bone marrow function (without the
support of cytokines or erythropoiesis-stimulating agent in preceding two weeks):
Absolute neutrophil count (ANC) greater than or equal to (>=) 1,500/cubic millimeters
(mm^3); Platelet count >=80,000/mm^3; Hemoglobin >=9.0 grams per deciliter (g/dL);
Liver function: (Total bilirubin less than or equal to (<=) 1.5 * upper limit of
normal (ULN) or direct bilirubin <= ULN for participants with total bilirubin levels
greater than (>)1.5*ULN (except participants with Gilbert's Syndrome, who must have a
total bilirubin < 3.0 mg/dL), and Alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) less than or equal to (<=) 2.5* institutional ULN); Renal
function: Creatinine clearance >=30 mL/min using the Cockcroft-Gault formula. 24-hour
creatinine clearance test will also be accepted for estimating renal function in
situations where Cockcroft-Gault formula is not a good predictor of estimating
adequate renal function
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Must not have had urothelial carcinoma or histological variant at any site outside of
the urinary bladder. Ta/T1/Carcinoma in situ (CIS) of the upper urinary tract
(including renal pelvis and ureter) is allowable if treated with complete
nephroureterectomy more than 24 months prior to initiating study

- Must not have diffuse CIS based on cystoscopy and biopsy. Diffuse, or multi-focal, CIS
is defined as the presence of at least 4 distinct CIS lesions in the bladder at the
time of the Screening re-TURBT

- Participants must not have evidence of cT4b, or N1-3, or M1 disease based on local
radiology staging (chest, abdomen, and pelvis must be performed using Computed
tomography [CT] or Magnetic resonance imaging [MRI]) within 42 days prior to
randomization

- Presence of any bladder or urethral anatomic feature that, in the opinion of the
investigator, may prevent the safe placement, indwelling use, or removal of TAR 200

- Evidence of bladder perforation during diagnostic cystoscopy. Participant is eligible
if perforation has healed prior to randomization

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/12/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
26/12/2029
Actual
Sample size
Target
550
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Flinders Medical Centre - Bedford Park
Recruitment postcode(s) [1] 0 0
5042 - Bedford Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Nebraska
Country [8] 0 0
United States of America
State/province [8] 0 0
New Jersey
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Oklahoma
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
South Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Tennessee
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Virginia
Country [18] 0 0
Argentina
State/province [18] 0 0
Bariloche
Country [19] 0 0
Argentina
State/province [19] 0 0
Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
Ciudad Automoma Buenos Aires
Country [21] 0 0
Argentina
State/province [21] 0 0
Ciudad Autónoma De Buenos Aires
Country [22] 0 0
Argentina
State/province [22] 0 0
Córdoba
Country [23] 0 0
Argentina
State/province [23] 0 0
La Rioja
Country [24] 0 0
Argentina
State/province [24] 0 0
Pergamino
Country [25] 0 0
Argentina
State/province [25] 0 0
Viedma
Country [26] 0 0
Austria
State/province [26] 0 0
Linz
Country [27] 0 0
Austria
State/province [27] 0 0
Salzburg
Country [28] 0 0
Austria
State/province [28] 0 0
Wien
Country [29] 0 0
Belgium
State/province [29] 0 0
Anderlecht
Country [30] 0 0
Belgium
State/province [30] 0 0
Antwerpen
Country [31] 0 0
Belgium
State/province [31] 0 0
Assebroek
Country [32] 0 0
Belgium
State/province [32] 0 0
Brugge
Country [33] 0 0
Belgium
State/province [33] 0 0
Kortrijk
Country [34] 0 0
Belgium
State/province [34] 0 0
Roeselare
Country [35] 0 0
Brazil
State/province [35] 0 0
Barretos
Country [36] 0 0
Brazil
State/province [36] 0 0
Belo Horizonte
Country [37] 0 0
Brazil
State/province [37] 0 0
Curitiba
Country [38] 0 0
Brazil
State/province [38] 0 0
Fortaleza
Country [39] 0 0
Brazil
State/province [39] 0 0
Jardim Blumenau
Country [40] 0 0
Brazil
State/province [40] 0 0
Jau
Country [41] 0 0
Brazil
State/province [41] 0 0
Natal
Country [42] 0 0
Brazil
State/province [42] 0 0
Porto Alegre
Country [43] 0 0
Brazil
State/province [43] 0 0
Presidente Prudente
Country [44] 0 0
Brazil
State/province [44] 0 0
Salvador
Country [45] 0 0
Brazil
State/province [45] 0 0
Santo André
Country [46] 0 0
Brazil
State/province [46] 0 0
Sao Jose do Rio Preto
Country [47] 0 0
Brazil
State/province [47] 0 0
Sao Paulo
Country [48] 0 0
Brazil
State/province [48] 0 0
São Paulo
Country [49] 0 0
Brazil
State/province [49] 0 0
Uberlândia
Country [50] 0 0
Canada
State/province [50] 0 0
Quebec
Country [51] 0 0
China
State/province [51] 0 0
Beijing
Country [52] 0 0
China
State/province [52] 0 0
Changchun
Country [53] 0 0
China
State/province [53] 0 0
Changsha Shi
Country [54] 0 0
China
State/province [54] 0 0
Changsha
Country [55] 0 0
China
State/province [55] 0 0
Chengdu
Country [56] 0 0
China
State/province [56] 0 0
Chongqing
Country [57] 0 0
China
State/province [57] 0 0
Guang Zhou Shi
Country [58] 0 0
China
State/province [58] 0 0
Guangzhou
Country [59] 0 0
China
State/province [59] 0 0
Hangzhou
Country [60] 0 0
China
State/province [60] 0 0
Jiaxing
Country [61] 0 0
China
State/province [61] 0 0
Nanjing
Country [62] 0 0
China
State/province [62] 0 0
Qingdao
Country [63] 0 0
China
State/province [63] 0 0
Shanghai
Country [64] 0 0
China
State/province [64] 0 0
Shenyang
Country [65] 0 0
China
State/province [65] 0 0
Tianjin
Country [66] 0 0
China
State/province [66] 0 0
Wenzhou Shi
Country [67] 0 0
China
State/province [67] 0 0
Wuhan
Country [68] 0 0
China
State/province [68] 0 0
Yantai
Country [69] 0 0
China
State/province [69] 0 0
Zhengzhou
Country [70] 0 0
Czechia
State/province [70] 0 0
Opava
Country [71] 0 0
Czechia
State/province [71] 0 0
Plzen-Bory
Country [72] 0 0
Czechia
State/province [72] 0 0
Praha 2
Country [73] 0 0
Czechia
State/province [73] 0 0
Praha 4
Country [74] 0 0
Czechia
State/province [74] 0 0
Praha 5
Country [75] 0 0
Czechia
State/province [75] 0 0
Praha 8
Country [76] 0 0
Czechia
State/province [76] 0 0
Praha
Country [77] 0 0
France
State/province [77] 0 0
Bordeaux
Country [78] 0 0
France
State/province [78] 0 0
Brest
Country [79] 0 0
France
State/province [79] 0 0
Caen Cedex 9
Country [80] 0 0
France
State/province [80] 0 0
Chambray-lès-Tours
Country [81] 0 0
France
State/province [81] 0 0
Hyeres
Country [82] 0 0
France
State/province [82] 0 0
Lille
Country [83] 0 0
France
State/province [83] 0 0
Limoges
Country [84] 0 0
France
State/province [84] 0 0
Lyon Cedex 03
Country [85] 0 0
France
State/province [85] 0 0
Marseille
Country [86] 0 0
France
State/province [86] 0 0
Montpellier
Country [87] 0 0
France
State/province [87] 0 0
Nimes
Country [88] 0 0
France
State/province [88] 0 0
Paris
Country [89] 0 0
France
State/province [89] 0 0
Quint-Fonsegrives
Country [90] 0 0
France
State/province [90] 0 0
Saint-Etienne Cedex 2
Country [91] 0 0
France
State/province [91] 0 0
Saint-Grégoire
Country [92] 0 0
France
State/province [92] 0 0
Suresnes
Country [93] 0 0
France
State/province [93] 0 0
Vandoeuvre-les-Nancy
Country [94] 0 0
France
State/province [94] 0 0
Villejuif Cedex
Country [95] 0 0
Germany
State/province [95] 0 0
Braunschweig
Country [96] 0 0
Germany
State/province [96] 0 0
Dresden
Country [97] 0 0
Germany
State/province [97] 0 0
Duisburg
Country [98] 0 0
Germany
State/province [98] 0 0
Düesseldorf
Country [99] 0 0
Germany
State/province [99] 0 0
Essen
Country [100] 0 0
Germany
State/province [100] 0 0
Frankfurt Am Main
Country [101] 0 0
Germany
State/province [101] 0 0
Frankfurt am Main
Country [102] 0 0
Germany
State/province [102] 0 0
Herne
Country [103] 0 0
Germany
State/province [103] 0 0
Markkleeberg
Country [104] 0 0
Germany
State/province [104] 0 0
Münster
Country [105] 0 0
Germany
State/province [105] 0 0
Nürnberg
Country [106] 0 0
Germany
State/province [106] 0 0
Trier
Country [107] 0 0
Greece
State/province [107] 0 0
Athens
Country [108] 0 0
Greece
State/province [108] 0 0
Holargos
Country [109] 0 0
Greece
State/province [109] 0 0
Maroussi
Country [110] 0 0
Greece
State/province [110] 0 0
Neo Faliro
Country [111] 0 0
Greece
State/province [111] 0 0
Thessaloniki
Country [112] 0 0
Greece
State/province [112] 0 0
Volos
Country [113] 0 0
Hungary
State/province [113] 0 0
Budapest N/a
Country [114] 0 0
Hungary
State/province [114] 0 0
Budapest
Country [115] 0 0
Hungary
State/province [115] 0 0
Debrecen
Country [116] 0 0
Hungary
State/province [116] 0 0
Nyíregyháza
Country [117] 0 0
India
State/province [117] 0 0
Amravati
Country [118] 0 0
India
State/province [118] 0 0
Bangalore
Country [119] 0 0
India
State/province [119] 0 0
Bikaner
Country [120] 0 0
India
State/province [120] 0 0
Nashik
Country [121] 0 0
India
State/province [121] 0 0
New Delhi
Country [122] 0 0
India
State/province [122] 0 0
Patna
Country [123] 0 0
India
State/province [123] 0 0
Pune
Country [124] 0 0
Italy
State/province [124] 0 0
Arezzo
Country [125] 0 0
Italy
State/province [125] 0 0
Candiolo
Country [126] 0 0
Italy
State/province [126] 0 0
Carpi
Country [127] 0 0
Italy
State/province [127] 0 0
Catania
Country [128] 0 0
Italy
State/province [128] 0 0
Foggia
Country [129] 0 0
Italy
State/province [129] 0 0
Genova
Country [130] 0 0
Italy
State/province [130] 0 0
Lugo
Country [131] 0 0
Italy
State/province [131] 0 0
Milano
Country [132] 0 0
Italy
State/province [132] 0 0
Milan
Country [133] 0 0
Italy
State/province [133] 0 0
Napoli
Country [134] 0 0
Italy
State/province [134] 0 0
Padova
Country [135] 0 0
Italy
State/province [135] 0 0
Pagani
Country [136] 0 0
Italy
State/province [136] 0 0
Pisa
Country [137] 0 0
Italy
State/province [137] 0 0
Pozzuoli
Country [138] 0 0
Italy
State/province [138] 0 0
Roma
Country [139] 0 0
Italy
State/province [139] 0 0
Rome
Country [140] 0 0
Italy
State/province [140] 0 0
Rozzano
Country [141] 0 0
Italy
State/province [141] 0 0
Siena
Country [142] 0 0
Italy
State/province [142] 0 0
Torino
Country [143] 0 0
Italy
State/province [143] 0 0
Varese
Country [144] 0 0
Italy
State/province [144] 0 0
Vicenza
Country [145] 0 0
Japan
State/province [145] 0 0
Iizuka
Country [146] 0 0
Japan
State/province [146] 0 0
Kanagawa
Country [147] 0 0
Japan
State/province [147] 0 0
Kashihara
Country [148] 0 0
Japan
State/province [148] 0 0
Kawagoe-Shi
Country [149] 0 0
Japan
State/province [149] 0 0
Kisarazu-shi
Country [150] 0 0
Japan
State/province [150] 0 0
Nagasaki-shi
Country [151] 0 0
Japan
State/province [151] 0 0
Osaka
Country [152] 0 0
Japan
State/province [152] 0 0
Shunan
Country [153] 0 0
Japan
State/province [153] 0 0
Tokyo
Country [154] 0 0
Japan
State/province [154] 0 0
Toyoake
Country [155] 0 0
Japan
State/province [155] 0 0
Ube
Country [156] 0 0
Japan
State/province [156] 0 0
Yokohama
Country [157] 0 0
Korea, Republic of
State/province [157] 0 0
Busan
Country [158] 0 0
Korea, Republic of
State/province [158] 0 0
Daegu
Country [159] 0 0
Korea, Republic of
State/province [159] 0 0
Gangnam Gu
Country [160] 0 0
Korea, Republic of
State/province [160] 0 0
Goyang-si
Country [161] 0 0
Korea, Republic of
State/province [161] 0 0
Hwasun-gun
Country [162] 0 0
Korea, Republic of
State/province [162] 0 0
Namdong
Country [163] 0 0
Korea, Republic of
State/province [163] 0 0
Seoul
Country [164] 0 0
Korea, Republic of
State/province [164] 0 0
Yangsan Si
Country [165] 0 0
Mexico
State/province [165] 0 0
Ciudad de México
Country [166] 0 0
Mexico
State/province [166] 0 0
Guadalajara
Country [167] 0 0
Mexico
State/province [167] 0 0
Juchitan De Zaragoza
Country [168] 0 0
Mexico
State/province [168] 0 0
Leon
Country [169] 0 0
Mexico
State/province [169] 0 0
Monterrey
Country [170] 0 0
Mexico
State/province [170] 0 0
Morelia
Country [171] 0 0
Mexico
State/province [171] 0 0
Oaxaca
Country [172] 0 0
Mexico
State/province [172] 0 0
San Luis Potosi
Country [173] 0 0
Mexico
State/province [173] 0 0
Zapopan
Country [174] 0 0
Poland
State/province [174] 0 0
Siedlce
Country [175] 0 0
Poland
State/province [175] 0 0
Skorzewo
Country [176] 0 0
Poland
State/province [176] 0 0
Warszawa
Country [177] 0 0
Poland
State/province [177] 0 0
Wroclaw
Country [178] 0 0
Portugal
State/province [178] 0 0
Almada
Country [179] 0 0
Portugal
State/province [179] 0 0
Coimbra
Country [180] 0 0
Portugal
State/province [180] 0 0
Lisboa
Country [181] 0 0
Portugal
State/province [181] 0 0
Lisbon
Country [182] 0 0
Portugal
State/province [182] 0 0
Porto
Country [183] 0 0
Russian Federation
State/province [183] 0 0
Barnaul
Country [184] 0 0
Russian Federation
State/province [184] 0 0
Ivanovo
Country [185] 0 0
Russian Federation
State/province [185] 0 0
Krasnoyarsk
Country [186] 0 0
Russian Federation
State/province [186] 0 0
Moscow
Country [187] 0 0
Russian Federation
State/province [187] 0 0
Obninsk
Country [188] 0 0
Russian Federation
State/province [188] 0 0
Omsk
Country [189] 0 0
Russian Federation
State/province [189] 0 0
Ryazan
Country [190] 0 0
Russian Federation
State/province [190] 0 0
Saint Petersburg
Country [191] 0 0
Russian Federation
State/province [191] 0 0
Saransk
Country [192] 0 0
Russian Federation
State/province [192] 0 0
Sochi
Country [193] 0 0
Russian Federation
State/province [193] 0 0
Tyumen
Country [194] 0 0
Russian Federation
State/province [194] 0 0
Ufa
Country [195] 0 0
Spain
State/province [195] 0 0
A Coruña
Country [196] 0 0
Spain
State/province [196] 0 0
Badalona
Country [197] 0 0
Spain
State/province [197] 0 0
Barcelona
Country [198] 0 0
Spain
State/province [198] 0 0
Granada
Country [199] 0 0
Spain
State/province [199] 0 0
Jerez de la Frontera
Country [200] 0 0
Spain
State/province [200] 0 0
Madrid
Country [201] 0 0
Spain
State/province [201] 0 0
Sabadell
Country [202] 0 0
Spain
State/province [202] 0 0
Santander
Country [203] 0 0
Spain
State/province [203] 0 0
Valencia
Country [204] 0 0
Taiwan
State/province [204] 0 0
Kaohsiung
Country [205] 0 0
Taiwan
State/province [205] 0 0
Taichung
Country [206] 0 0
Taiwan
State/province [206] 0 0
Tainan
Country [207] 0 0
Taiwan
State/province [207] 0 0
Taipei
Country [208] 0 0
Taiwan
State/province [208] 0 0
Taoyuan
Country [209] 0 0
Turkey
State/province [209] 0 0
Adana
Country [210] 0 0
Turkey
State/province [210] 0 0
Ankara
Country [211] 0 0
Turkey
State/province [211] 0 0
Balcova
Country [212] 0 0
Turkey
State/province [212] 0 0
Fatih
Country [213] 0 0
Turkey
State/province [213] 0 0
Gaziantep
Country [214] 0 0
Turkey
State/province [214] 0 0
Istanbul
Country [215] 0 0
Turkey
State/province [215] 0 0
Izmir
Country [216] 0 0
Turkey
State/province [216] 0 0
Malatya
Country [217] 0 0
Turkey
State/province [217] 0 0
Melikgazi
Country [218] 0 0
Turkey
State/province [218] 0 0
Seyhan
Country [219] 0 0
Ukraine
State/province [219] 0 0
Chernihiv
Country [220] 0 0
Ukraine
State/province [220] 0 0
Dnipro
Country [221] 0 0
Ukraine
State/province [221] 0 0
Kharkiv
Country [222] 0 0
Ukraine
State/province [222] 0 0
Kherson
Country [223] 0 0
Ukraine
State/province [223] 0 0
Kiev
Country [224] 0 0
Ukraine
State/province [224] 0 0
Kyiv
Country [225] 0 0
Ukraine
State/province [225] 0 0
Lviv

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in
participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus
concurrent chemoradiotherapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04658862
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trials
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Contact
Address 0 0
Country 0 0
Phone 0 0
844-434-4210
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04658862